How genetic differences change tissue factor, a key blood clotting protein
Genetic architecture of tissue factor expression
This project looks at whether rare genetic changes in the gene for tissue factor affect blood clotting and bleeding risk in people.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beth Israel Deaconess Medical Center NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11145263 on NIH RePORTER |
What this research studies
Researchers will search for rare DNA changes in the F3 gene that controls tissue factor and study how those changes alter tissue factor levels or function. They will examine the gene's promoter, coding sequence, and 3' untranslated region, including how microRNAs can turn the gene down, using lab biochemical tests and molecular assays. The team will combine those lab results with human genetic data and samples to link specific variants to histories of clotting (like heart attack, stroke, or VTE) or unexplained bleeding. The work aims to find people whose clotting risk is driven by previously undetected genetic changes in tissue factor.
Who could benefit from this research
Good fit: Ideal candidates would include people with unexplained blood clots (heart attack, stroke, venous thromboembolism), unexplained bleeding, or a family history of clotting or bleeding disorders who can provide genetic samples and medical history.
Not a fit: People whose bleeding or clotting problems are already explained by other diagnosed conditions or who are currently on anticoagulant therapy for clearly identified causes may not gain direct benefit from this project.
Why it matters
Potential benefit: If successful, this work could reveal genetic causes of abnormal clotting or bleeding and help identify people at higher or lower risk so care can be personalized.
How similar studies have performed: Prior research has connected tissue factor levels to clotting risk and has begun to map regulatory microRNAs, but applying rare human variant discovery across promoter, coding, and 3'UTR regions in this integrated way is relatively new.
Where this research is happening
Boston, United States
- Beth Israel Deaconess Medical Center — Boston, United States (Active)
Researchers
- Principal investigator: Schulman, Sol — Beth Israel Deaconess Medical Center
- Study coordinator: Schulman, Sol
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.